Medicenna Therapeutics

OverviewSuggest Edit

Medicenna Therapeutics is an immunotherapy company focused on oncology. It develops and commercializes selective versions of IL-2, IL-4, and IL-13 Superkines and Empowered Cytokines (ECs) for the treatment of a range of cancers. The company offers a technology platform that delivers potent cell-killing agents for cancer as well as actively alters the immunosuppressive tumor micro-environment without harming healthy cells.
TypePublic
Founded2012
Websitemedicenna.com

Latest Updates

Employees (est.) (Apr 2020)7
Share Price (Sept 2020)$3.8 (-2%)
Cybersecurity ratingAMore

Medicenna Therapeutics Financials and Metrics

Medicenna Therapeutics Revenue

Market capitalization (15-Sept-2020)

227.1m

Closing stock price (15-Sept-2020)

3.8
Medicenna Therapeutics's current market capitalization is $227.1 m.
Show all financial metrics

Medicenna Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Medicenna Therapeutics Online and Social Media Presence

Embed Graph

Medicenna Therapeutics Frequently Asked Questions

  • When was Medicenna Therapeutics founded?

    Medicenna Therapeutics was founded in 2012.

  • How many employees does Medicenna Therapeutics have?

    Medicenna Therapeutics has 7 employees.

  • Who are Medicenna Therapeutics competitors?

    Competitors of Medicenna Therapeutics include Crescendo Biologics, Socium Therapeutics and Autonomous Therapeutics.